Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $565.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective upped by equities researchers at Robert W. Baird from $503.00 to $565.00 in a research note issued to investors on Thursday. Robert W. Baird’s target price points to a potential upside of 19.06% from the company’s previous close.

Several other research firms also recently weighed in on ISRG. Evercore ISI lifted their target price on shares of Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. upped their price target on Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Barclays increased their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Morgan Stanley upped their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Finally, Citigroup boosted their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $484.15.

Intuitive Surgical Stock Performance

NASDAQ ISRG traded down $2.04 on Thursday, hitting $474.55. 651,718 shares of the stock traded hands, compared to its average volume of 1,459,238. The business’s fifty day moving average is $482.49 and its two-hundred day moving average is $436.65. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $496.48. The firm has a market capitalization of $168.32 billion, a price-to-earnings ratio of 85.71, a PEG ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the company earned $1.18 EPS. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. Analysts expect that Intuitive Surgical will post 5.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Brosius sold 2,115 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the transaction, the insider now owns 295 shares of the company’s stock, valued at approximately $145,113.45. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the transaction, the insider now owns 295 shares in the company, valued at $145,113.45. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock worth $25,528,753 in the last quarter. 0.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Intuitive Surgical

A number of large investors have recently added to or reduced their stakes in ISRG. Ullmann Wealth Partners Group LLC boosted its holdings in Intuitive Surgical by 1.6% in the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock valued at $653,000 after acquiring an additional 21 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC raised its holdings in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after purchasing an additional 23 shares in the last quarter. Daymark Wealth Partners LLC lifted its position in Intuitive Surgical by 0.3% during the third quarter. Daymark Wealth Partners LLC now owns 7,027 shares of the medical equipment provider’s stock valued at $3,452,000 after buying an additional 24 shares during the period. Indiana Trust & Investment Management CO lifted its position in Intuitive Surgical by 5.3% during the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares during the period. Finally, Hoxton Planning & Management LLC boosted its stake in Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 25 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.